Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370

Reuters2026/08/18 20:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Malik Fady Ibraham, EVP Research & Development at Cytokinetics, exercised stock options for 3,500 shares on Aug. 18, 2026 at USD 7.8.
Same day sale of 3,500 shares at USD 75.82; direct holdings fell to 153,902 shares.
Non-Qualified Stock Option (Right to Buy) balance declined to 30,386 options, exercisable through Feb. 27, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000088), on August 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370

You may also like

Crypto prices